Kurata, Y.; Mouri, A.; Imai, H.; Endo, S.; Tsukamoto, K.; Masaki, K.; Hashimoto, K.; Miura, Y.; Shiono, A.; Yamaguchi, O.;
et al. Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study. Medicina 2025, 61, 994.
https://doi.org/10.3390/medicina61060994
AMA Style
Kurata Y, Mouri A, Imai H, Endo S, Tsukamoto K, Masaki K, Hashimoto K, Miura Y, Shiono A, Yamaguchi O,
et al. Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study. Medicina. 2025; 61(6):994.
https://doi.org/10.3390/medicina61060994
Chicago/Turabian Style
Kurata, Yuhei, Atsuto Mouri, Hisao Imai, Satoshi Endo, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi,
and et al. 2025. "Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study" Medicina 61, no. 6: 994.
https://doi.org/10.3390/medicina61060994
APA Style
Kurata, Y., Mouri, A., Imai, H., Endo, S., Tsukamoto, K., Masaki, K., Hashimoto, K., Miura, Y., Shiono, A., Yamaguchi, O., Nakagawa, J., Kaira, K., Kobayashi, K., & Kagamu, H.
(2025). Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study. Medicina, 61(6), 994.
https://doi.org/10.3390/medicina61060994
